A new once-weekly basal insulin injection demonstrated similar efficacy and safety and a lower rate of low blood sugar episodes compared with a daily basal insulin, according to a phase 2 clinical trial. The study results compared an investigational drug called basal insulin Fc (BIF) with insulin degludec, a commercially available long-lasting daily insulin, in patients with type 2 diabetes.
source https://www.sciencedaily.com/releases/2021/03/210321215440.htm
Monday, 22 March 2021
Related Posts
New study unravels Darwin's 'abominable mystery' surrounding origin of flowering plantsThe origin of flowering plants famously puzzled Charles Darwin, who de… Read More
Up-trending farming and landscape disruptions threaten Paris climate agreement goalsEarth system science researchers conducted an analysis of greenhouse g… Read More
Study reveals precarious employment on the rise long before COVID-19Researchers have used a new approach to measure precarious, or low-qua… Read More
635 million-year-old fungi-like microfossil that bailed us out of an ice age discoveredA team of scientists has discovered the remains of a fungi-like microf… Read More
Putting bugs on the menu, safelyThe thought of eating insects is stomach turning for many, but new res… Read More
New catalyst moves seawater desalination, hydrogen production closer to commercializationSeawater is abundant and cheap, making it a tempting resource to meet … Read More
0 comments: